Emerging evidence suggests that ANXA1 may contribute to immune suppression within TME via its functional interaction with the EGFR pathway, a key regulator of cell proliferation and tumor progression in both colon cancer and RC [38,202]. This evidence concerns the gene EGFR and malignant colon neoplasm.